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RESULTS 
 While confirmed cases of serotonin syndrome (SS) have been associated  
 with linezolid, the incidence in patients receiving linezolid in combination with  
 other serotonergic medications has not been well established 
 Incidence in published retrospective studies ranges from 0.54% to  
 4.17%1-4 
 
 The Hunter Serotonin Toxicity Criteria (HSTC) are the most widely accepted  
 criteria used to diagnosis SS 
Any of the following in the presence of a serotonergic agent 
Spontaneous clonus 
Inducible clonus AND agitation OR diaphoresis 
Ocular clonus AND agitation OR diaphoresis 
Tremor AND hyperreflexia 
Hypertonicity AND temperature > 38
 
C AND ocular clonus 
 Prospectively determine the incidence of SS in hospitalized patients  
 receiving linezolid and concomitant serotonergic therapy 
 IRB-approved prospective analysis 
 
 Inclusion criteria: ≥ 18 years of age, receipt of linezolid between March 1,  
 2012 and June 15, 2012 
 
 Exclusion criteria: none 
 
 Primary outcome: development of SS, by definitive diagnosis via the primary  
 patient care team or by satisfying the HSTC 
 
 Concomitant serotonergic therapy was defined as any agent known to affect  
 serotonin activity  
 
 A CPOE-based report of active linezolid orders was generated daily to  
 capture patients for inclusion 
 Electronic health records (EHR) of included patients were assessed for  
 signs and symptoms of SS daily until development of SS or hospital  
 discharge 
 If documentation in the EHR suggested possible SS, the primary  
 patient care team was contacted to confirm 
 130 unique courses of linezolid were received by 121 unique patients  
 37 (28.5%) were in patients who received concomitant serotonergic therapy 
Table 1. Demographic Information 
n = 37 
Median Age (IQR) [years] 64 (50-75) 
Female (%) 25 (67.6%) 
Median Length of Stay (IQR) [days] 13 (7-19) 
Median Duration of Linezolid Therapy (IQR) [hours] 78 (44-167) 
Pulmonary Disease 45.9% 
Cardiovascular Disease 27.0% 
Seizure Disorder 18.9% 
Liver Disease 2.7% 
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Figure 3. Concomitant 
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SSRIs, selective serotonin reuptake inhibitors; 
SNRIs, serotonin norepinephrine reuptake 
inhibitors; SGAs, second generation antipsychotics  
Figure 4. Agents Continued 
as Home Medication 
 No patients receiving linezolid in combination with other serotonergic therapy  
 developed the primary outcome 
 
 The following symptoms were observed 
 Six patients were agitated 
 Five during combination therapy 
 Two of the five were agitated throughout admission 
 The other was agitated 9 days after completion of linezolid 
 One patient was diaphoretic during combination therapy 
 
 Although the primary team did not make a diagnosis of SS, the ID consult  
 team listed SS on the differential for a patient hospitalized with traumatic  
 brain injury and sympathetic storming who had persistent fever, tachycardia,  
 and flushing 
 
 The incidence of linezolid-associated SS in 37 patients receiving linezolid in 
combination with other known serotonergic agents  at a large academic 
medical center was zero 
 
 To our knowledge this is the first prospective study investigating the 
incidence of linezolid-associated SS 
 
 Limitations 
 Single center  
 Short study period 
 Patients were not physically assessed daily by investigators 
 
 Linezolid-associated SS is rare despite use with serotonergic therapy  
 at West Virginia University Hospitals 
 
 Further observation is needed in order to describe the true incidence  
 of this life-threatening reaction and related risk factors  
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